LY3541860 在复发性多发性硬化症成人参与者中的研究
一项适应性 2a/2b 期、随机、双盲、平行组研究,旨在调查 LY3541860 与安慰剂相比在减缓复发性多发性硬化症成年参与者中新 T1 钆增强病变发生方面的安全性和有效性
The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Milan、意大利、20133
- Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta-VIA MANGIAGALLI 3
-
-
-
-
-
Riga、拉脱维亚、LV-1002
- Pauls Stradins Clinical Univeristy Hospital
-
-
-
-
-
Bratislava、斯洛伐克、826 06
- Nemocnica Ruzinov
-
-
-
-
-
Poissy、法国、78303
- Centre Hospitalier Intercommunal - Site de Poissy
-
-
-
-
-
Bydgoszcz、波兰、85-796
- Neurocentrum Bydgoszcz sp. z o.o.
-
Katowice、波兰、40-686
- NEURO-MEDIC Sp. z o. o.
-
Katowice、波兰、40-060
- Specjalistyczna Praktyka Lekarska prof. Grzegorz Opala
-
Katowice、波兰、40-571
- M.A. - LEK A.M. Maciejowscy SC. Centrum Terapii SM
-
Lublin、波兰、20-064
- Clinirem
-
Poznan、波兰、61-853
- Niepubliczny Zaklad Opieki Zdrowotnej NEURO-KARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy
-
Warsaw、波兰、02-677
- ETG Neuroscience - PPDS
-
Zabrze、波兰、41-800
- IBISMED Wielospecjalistyczne Centrum Medyczne
-
Żory、波兰、44-240
- ProNeuro Centrum Medyczne
-
-
-
-
Florida
-
Gulf Breeze、Florida、美国、32561
- Panhandle Research and Medical Clinic
-
Winter Park、Florida、美国、32789
- Conquest Research LLC - Winter Park - ClinEdge - PPDS
-
-
Illinois
-
Northbrook、Illinois、美国、60062
- Consultants in Neurology
-
-
Missouri
-
Ozark、Missouri、美国、65721-5315
- Sharlin Health and Neurology
-
-
South Carolina
-
Greer、South Carolina、美国、29605
- Premier Neurology
-
-
Tennessee
-
Knoxville、Tennessee、美国、37922
- Hope Neurology
-
-
-
-
-
Nottingham、英国、NG7 2UH
- Queen's Medical Centre
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Participants must meet criteria for relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis based on the 2017 revision of the McDonald diagnostic criteria (Thompson et al. 2018) with a relapsing course (RMS) activity according to Klineova and Lublin 2018.
-
Participants must have 1 of these:
- at least 1 documented relapse within the previous year
- at least 2 documented relapses within the previous 2 years, or
- at least 1 active GdE brain lesion on an MRI scan in the past 180 days prior to screening.
-
Have an Expanded Disability Status Scale (EDSS) score of less than or equal to (≤) 5.5 at screening and randomization.
Exclusion Criteria:
-
Have had a diagnosis of:
- primary progressive multiple sclerosis (MS) according to the 2017 revision of McDonald diagnostic criteria (Thompson et al. 2018), or
- nonactive secondary progressive MS ( Klineova and Lublin 2018).
-
Meet criteria for neuromyelitis optica spectrum disorder (Wingerchuk and Lucchinetti 2022).
-
Have a history of clinically significant central nervous system (CNS) disease.
-
Have had a confirmed relapse with systemic corticosteroid administration <30 days prior to randomization.
-
Have more than 20 active GdE brain lesions on screening MRI scan.
-
Have received any of these medications or treatments.
-
Have a current or recent acute, active infection.
-
Have current serious or unstable illnesses.
-
Have any other clinically important abnormality at screening or baseline.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:LY3541860 High Dose
Participants received a high dose of LY3541860 administered intravenously (IV) over a period of 36 weeks. |
Administered IV |
|
实验性的:Placebo / LY3541860 Low Dose
Participants received LY3541860-matching placebo for 12 weeks, followed by a low dose of LY3541860 administered intravenously (IV) over a period of 24 weeks. |
Administered IV Administered IV |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions
大体时间:12 Weeks
|
The cumulative number of new T1 gadolinium-enhancing (GdE) lesions observed on MRI scans during the treatment period. Treatment group means were estimated using an augmented inverse propensity weighted (AIPW) estimator with a negative binomial regression outcome model adjusted for geographic region (North America versus Rest of World) and presence of T1 GdE lesions at baseline (0 or ≥1). |
12 Weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Cumulative Number of Total Number of T1 GdE Lesions
大体时间:12 Weeks
|
The cumulative number of total number of T1 gadolinium-enhancing (GdE) lesions observed on MRI scans during the treatment period. Treatment group means were estimated using an augmented inverse propensity weighted (AIPW) estimator with a negative binomial regression outcome model adjusted for geographic region (North America versus Rest of World) and presence of T1 GdE lesions at baseline (0 or ≥1). |
12 Weeks
|
|
Cumulative Number of New and/or Enlarging T2 Lesions
大体时间:12 Weeks
|
The cumulative number of new and/or enlarging T2 lesions identified on MRI scans during the treatment period. Treatment group means were estimated using an augmented inverse propensity weighted (AIPW) approach with a negative binomial regression outcome model adjusted for geographic region (North America vs Rest of World) and presence of T1 gadolinium-enhancing lesions at baseline (0 vs ≥1). |
12 Weeks
|
|
Pharmacokinetics (PK): Observed Plasma Trough Concentrations of LY3541860 at Week 12
大体时间:Predose at Week 12
|
Observed Plasma trough concentrations (Ctrough) of LY3541860. |
Predose at Week 12
|
合作者和调查者
调查人员
- 研究主任:Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)、Eli Lilly and Company
出版物和有用的链接
有用的网址
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 18548
- J3K-MC-KIAB (其他标识符:Eli Lilly and Company)
- 2023-503289-22-00 (其他标识符:EU Trial Number)
- 2023 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD 共享时间框架
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD 共享访问标准
research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD 共享支持信息类型
- 研究方案
- 树液
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.